Keryx Announces Appointment of John P. Butler to its Board of Directors
December 10, 2015 08:00 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 10, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
Keryx Biopharmaceuticals Announces Webcast of Presentation at Oppenheimer's 26th Annual Healthcare Conference
December 01, 2015 09:05 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Dec. 01, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
Keryx Biopharmaceuticals Announces Participation at Two Upcoming Investor Conferences
November 03, 2015 16:05 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Nov. 03, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
Keryx Biopharmaceuticals Announces Third Quarter 2015 Financial Results
October 29, 2015 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
– Growth in third quarter Auryxia™ (ferric citrate) product sales driven by increased breadth and depth of prescribers – – Keryx well positioned with strengthened cash position to support Auryxia...
Keryx Biopharmaceuticals to Host Conference Call of Third Quarter 2015 Financial Results on Thursday, October 29, 2015
October 21, 2015 09:05 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Oct. 21, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal...
Keryx Biopharmaceuticals Announces $125 Million Private Placement of Convertible Senior Notes With The Baupost Group, L.L.C.
October 15, 2015 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
Keryx implements plan to significantly reduce its annual cash operating expenses, beginning in 2016Increased cash position expected to take Auryxia™ (ferric citrate) franchise to cash flow positive ...
Keryx Receives European Approval for Fexeric(R) (ferric citrate coordination complex) for the Treatment of Hyperphosphatemia in Adults With Chronic Kidney Disease
September 24, 2015 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) today announced that the European Commission has approved Fexeric® (ferric citrate coordination complex)...
Keryx Biopharmaceuticals Announces Participation at Upcoming Investor Conferences
September 09, 2015 08:30 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc, (NASDAQ:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for patients with renal disease,...
Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results
August 05, 2015 07:00 ET
|
Keryx Biopharmaceuticals, Inc.
Majority of phosphate binder patients today have access to Auryxia™
CHMP recently adopted a positive opinion for Fexeric® (ferric citrate coordination complex) in the EU
Enrollment...
Keryx Biopharmaceuticals to Host Conference Call of Second Quarter 2015 Financial Results on Wednesday, August 5, 2015
July 28, 2015 16:05 ET
|
Keryx Biopharmaceuticals, Inc.
BOSTON, July 28, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease,...